α/β t-cell receptor and methods of using it
View Patent ↗The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or bispecific comprising said TCR, said cell, said clone or said vector; use of said TCR or said cell or said clone or said vector or said pharmaceutical composition or bispecific to treat cancer; and a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition or bispecific comprising said TCR.
1. A vector encoding a T-cell receptor (TCR) wherein the TCR comprises
(i) an α chain that comprises the CDR1α, CDR2α, and CDR3α amino acid sequences of the α chain amino acid sequence set forth in SEQ ID NO: 7; and
(ii) a β chain that comprises the CDR1β, CDR2β, and CDR3β amino acid sequences of the β chain amino acid sequence set forth in SEQ ID NO: 8.
2. The vector of claim 1 wherein the TCR is MR1-restricted.
3. A T-cell comprising the vector of claim 1 .
4. A pharmaceutical composition comprising the T cell of claim 3 .
5. A method of treating cancer in an individual in need thereof comprising administering to the individual the T-cell of claim 3 , wherein the individual has a cancer selected from the group consisting of colorectal cancer, lung cancer, kidney cancer, prostate cancer, cervical cancer, melanoma, bone cancer, breast cancer, ovarian cancer, and blood cancer.
6. The method of claim 5 , wherein the T-cell is administered in combination with an anti-tumor agent.
7. The vector of claim 1 , wherein the TCR is a chimeric TCR.
8. The vector of claim 1 , wherein the vector is a lentiviral vector.
9. A pharmaceutical composition comprising the vector of claim 1 .
10. A method of killing a cancer cell that expresses MR1 in an individual, the method comprising administering to the individual the T cell of claim 3 .